Celem działalności PBKM jest zapewnienie bezpieczeństwa rodziny na wypadek wystąpienia ciężkiej choroby wymagającej przeszczepienia komórek macierzystych u dawcy lub członków jego najbliższej rodziny. Obecnie PBKM prowadzi działalność w krajach Europy Środkowo-Wschodniej (Polska, Łotwa, Węgry, Rumunia) oraz południowej (Hiszpania, Włochy, Turcja) a poprzez partnerów biznesowych również w innych krajach – m.in. Serbii, Chorwacji, Bośni i Hercegowinie, Szwecji ,Wielkiej Brytanii i Ukrainie. Za rok 2016 i 2017 Grupa FamiCord była liderem rynku europejskiego pod względem nowo pozyskiwanych próbek. Aktualnie przechowuje w swoich laboratoriach ponad 215 tysięcy próbek krwi pępowinowej lub tkanek.

PBKM (Famicord Group) – Key facts

PBKM S.A. operating in Europe under umbrella of Famicord Group is the largest stem cell bank in Europe collecting and storing human stem cells isolated from cord blood and other tissues taken after childbirth in terms of new samples collected. Total cumulated number of stored samples of different biological materials (like cord tissue, placental blood etc.) exceeds 215.000. On top of family banking activity the Group runs public bank cord blood bank sponsored with own funds with an inventory of almost 4000 units.

Famicord Group has supplied stem cells for treatment of over 1300 patients in Europe and USA (37 of cord blood, 700+ of MSC derived from cord tissue and 600+ of bone marrow and peripheral blood). Famicord’s mother company – PBKM – holds 6 permissions of Polish Main Pharmaceutical Inspectorate for production of ATMP in a hospital exemption procedure.

Famicord was 2nd European bank granted by AABB (formerly American Association of Blood Banks) in 2007 with accreditation for its local Polish laboratory in Warsaw. Today, also the laboratories in Spain and Hungary are AABB accredited. In November 2016 PBKM as the only family bank in Europe became a member of EBMT (European Bone Marrow Transplantation Organization). PBKM holds also permission of FDA to export samples to USA.

Famicord’s companies in Poland and Hungary received in the past several grants mostly related with improvement of processing technology of stem cells. Currently there are 3 more projects running in consortia with a few universities related with usage of stem cells from umbilical cord and adipose tissue in clinical trials in cardiology, diabetics and dermatology. Additionally PBKM started work on a new own clinical trial for treatment of ALS with a budget of 6m Euro.

Famicord Group operates 7 own stem cell processing laboratories located in 5 countries (Spain, Poland, Turkey, Hungary and Romania) and cooperates with a few partners’ laboratories in Germany, Switzerland, USA and Poland.

Famicord has developed also a network of cooperating partners in several countries i.e. Sweden, UK, Ukraine and Balkan countries. Famicord member companies hold top positions in stem cell banking in the following markets: Spain – number 1, Poland – number 1, Hungary – number 1, Latvia – number 1, Turkey – number 1, Romania – number 2; Italy – 6.

Famicord Group hires over 350 people in Europe. Consolidated revenue in 2016 reached 30m Euro (1st position in Europe), EBITDA profit reached 8m Euro (1st position in Europe), net profit exceeded 5m Euro (1st position in Europe).

According to analyst expectations in 2017 Famicord Group reached 35m Euro revenue and over 10m Euro EBITDA.  Famicord Group is number 1 in Europe in terms of newly collected samples holding over 20% of European market share.

Famicord’s mother company – PBKM is listed on Warsaw Stock Exchange with a market cap of ~85m Euro. The important shareholders of Famicord Group are among the others: Altus TFI – mutual fund managing assets of EUR 3,5+ billion, Nationale Nederlanden OFE – pension fund managing assets of EUR 9+ billion, Aegon, Allianz, Government of Norway through its national Oil Fund any many other mostly financial shareholders.